Organogenesis Holdings Inc (ORGO)vsZoetis Inc (ZTS)
ORGO
Organogenesis Holdings Inc
$2.44
+1.24%
HEALTHCARE · Cap: $317.74M
ZTS
Zoetis Inc
$116.71
+0.67%
HEALTHCARE · Cap: $51.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 1578% more annual revenue ($9.47B vs $564.17M). ZTS leads profitability with a 28.2% profit margin vs 6.6%. ORGO trades at a lower P/E of 16.5x. ORGO earns a higher WallStSmart Score of 67/100 (B-).
ORGO
Strong Buy67
out of 100
Grade: B-
ZTS
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+46.7%
Fair Value
$7.02
Current Price
$2.44
$4.58 discount
Margin of Safety
-29.1%
Fair Value
$99.69
Current Price
$116.71
$17.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 78.1% year-over-year
Attractively priced relative to earnings
Strong operational efficiency at 28.9%
Every $100 of equity generates 66 in profit
Strong operational efficiency at 34.7%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Smaller company, higher risk/reward
6.6% margin — thin
Expensive relative to growth rate
Trading at 14.9x book value
3.0% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ORGO
The strongest argument for ORGO centers on Price/Book, Revenue Growth, P/E Ratio. Revenue growth of 78.1% demonstrates continued momentum.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.2% and operating margin at 34.7%.
Bear Case : ORGO
The primary concerns for ORGO are Market Cap, Profit Margin.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.85 is elevated, increasing financial risk.
Key Dynamics to Monitor
ORGO profiles as a hypergrowth stock while ZTS is a value play — different risk/reward profiles.
ORGO carries more volatility with a beta of 1.39 — expect wider price swings.
ORGO is growing revenue faster at 78.1% — sustainability is the question.
ZTS generates stronger free cash flow (732M), providing more financial flexibility.
Bottom Line
ORGO scores higher overall (67/100 vs 64/100) and 78.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Organogenesis Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?